[go: up one dir, main page]

WO2023093007A1 - Site pour l'expression stable de la protéine dans le gène de la cellule cho nw_003614889.1, et son utilisation - Google Patents

Site pour l'expression stable de la protéine dans le gène de la cellule cho nw_003614889.1, et son utilisation Download PDF

Info

Publication number
WO2023093007A1
WO2023093007A1 PCT/CN2022/099466 CN2022099466W WO2023093007A1 WO 2023093007 A1 WO2023093007 A1 WO 2023093007A1 CN 2022099466 W CN2022099466 W CN 2022099466W WO 2023093007 A1 WO2023093007 A1 WO 2023093007A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
site
gene
cho
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/099466
Other languages
English (en)
Chinese (zh)
Inventor
陈蕴
金坚
瞿丽丽
丁学峰
李华钟
蔡燕飞
朱景宇
杨兆琪
鲁晨
戴云峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangnan University
Original Assignee
Jiangnan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangnan University filed Critical Jiangnan University
Publication of WO2023093007A1 publication Critical patent/WO2023093007A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters

Definitions

  • the invention relates to a site for stably expressing protein in CHO cell gene NW_003614889.1 and an application thereof, belonging to the field of gene technology.
  • CHO cells Chinese hamster ovary (CHO) cells were established in Dr. Theodore T. Puck's laboratory in 1957. They are immortalized non-secreting cells that rarely secrete endogenous proteins; Post-translational modifications closer to human natural proteins, less susceptible to human virus infection, and large-scale culture in serum-free medium with defined chemical components, etc., are widely used in the field of biopharmaceuticals, and more than 70% of proteins are produced drug.
  • mammalian cells CHO cells have a long culture cycle and high culture costs.
  • the demand for recombinant products such as monoclonal antibodies continues to increase. The continuous growth of demand means that the specific productivity still needs to be optimized.
  • the expression level can be increased by increasing the copy number of the gene, developing a new strong promoter, finding a suitable enhancer, etc.
  • the expression level of most CHO cells is unstable during the long-term culture process, which directly affects the supervision of the product by the regulatory authorities. Approval and listing issues. Therefore, it is very important to construct a CHO expression strain that stably and highly expresses the target gene for the development and marketing of protein drugs.
  • Random integration is the most mature traditional method for constructing protein expression systems, but obtaining stable high-expression cell lines through random integration requires multiple screenings, which is time-consuming and expensive.
  • the loss of expression stability of the cells in the later stage of culture is completely unpredictable: this instability may not occur at all; it may also gradually appear after numerous cell divisions; It is also possible that apparent instability occurs after only a few generations of cell division.
  • the stability issue will not only affect the time to market of the product, but will also conflict with drug regulatory management.
  • the information of random integration sites is not clear, and the site effect of exogenous gene integration will also lead to a significant decrease in the expression level of the target gene. According to existing literature reports, this instability of recombinant CHO cell lines occurs in all recombinant CHO cell lines, making the problem of unstable expression an extremely common problem.
  • the present invention provides a site for stably expressing proteins in the genome of CHO cells.
  • the screening process and time in the cell construction process reduce the cost of research and development.
  • the first object of the present invention is to provide a stable protein expression site in the CHO cell genome, and the stable protein expression site is located in the 103331-103531 base of the CHO cell gene NW_003614889.1.
  • nucleotide sequence of bases 103331-103531 of the CHO cell gene NW_003614889.1 is shown in SEQ ID NO.1.
  • the site for stably expressing the protein can be recognized by the 5'NNNNNNNNNNNNNNNNNNNGG 3' sequence of the CRISPR/Cas9 technology.
  • the 5'NNNNNNNNNNNNNNNNNNNNNNNNNNNNNGG 3' sequence in the embodiment of the present invention selects the following 9 sequences: 5'-ATCTTACTTTGCAACTACCAAGG-3', 5'-CACTTTTATCTAACACTGGCCAGG-3', 5'-AGCAACACTTTTATCTAACACTGG-3', 5'-GCACTCTGTGTGGAGCAAAGAGG-3', 5'-GCAAATGAGTAAAGTTCTCCTGG-3', 5'-TGCAGTGATAGCACTCTGTGTGG-3', 5'-AACAGGATGAAAATGTATGGAGG-3', 5'-TTCATCCTGTTCTCTGTTCTGGG-3', 5'-TTTCATCCTGTTCTCTGTTCTGG- 3'.
  • the above-mentioned 9 groups of sequences are distributed within the 103331-103531 bases of the CHO cell gene NW_003614889.1 and cover most of the upper, middle and downstream sequences within the 200 bases of the present invention, indicating that the 200 bases of the present invention All bases can be used as sites for stably expressing proteins.
  • the present invention does not limit the above nine groups of sequences.
  • the above nine groups of sequences are only used as the preferred technical means to introduce the coding gene of the target protein into the stable expression site.
  • the purpose of stably expressing the protein of the present invention can be achieved.
  • the protein is a protein with a molecular weight less than 160KDa.
  • the protein is one of polypeptides, functional proteins, antibodies, and fusion proteins.
  • the second object of the present invention is to provide the application of the stable protein expression sites in the CHO cell genome in the stable expression of foreign proteins in CHO cells.
  • the application specifically involves constructing a gene encoding an exogenous protein or polypeptide at the site of stably expressing the protein in the CHO cell gene NW_003614889.1.
  • the third object of the present invention is to provide an expression vector for expressing protein in CHO cells, the coding gene of the protein is located between the 5' homology arm and the 3' homology arm of the expression vector region, the 5' homology arm and the 3' homology arm are sequences with a length of 600 bp upstream and downstream of the stable protein expression site respectively.
  • the expression vector is a vector suitable for expression in CHO cells.
  • the expression vector also includes a promoter sequence located upstream of the gene encoding the protein, and the promoter controls the expression of the protein.
  • the promoters are: CMV (strong mammalian expression promoter derived from human cytomegalovirus), EF-1a (strong mammalian expression promoter derived from human elongation factor 1 ⁇ ), SV40 (simian vacuolar virus 40 derived mammalian expression promoter), PGK1 (mammalian promoter derived from phosphoglycerate kinase gene), UBC (mammalian promoter derived from human ubiquitin C gene), humanbeta actin ( ⁇ -actin gene derived mammalian promoter), CAG (strong hybrid mammalian promoter), etc.
  • an expression vector for expressing a protein in CHO cells comprising the following steps: inserting the gene encoding the protein into the region between the 5'arm and the 3'arm of the plasmid, making the protein encoding The gene is located downstream of the promoter and is regulated by the promoter to obtain the expression vector for expressing the protein in CHO cells.
  • the fourth object of the present invention is to provide a CHO recombinant cell with site-specific integration and stable expression of protein.
  • the CHO recombinant cell is obtained by using the expression vector for expressing protein in CHO cells and the sgRNA corresponding to the target sequence. Plasmids and Cas9 plasmids were transformed into CHO cells.
  • the target sequence is preferably 5'-ATCTTACTTTGCAACTACCAAGG-3', 5'-CACTTTTATCTAACACTGGCCAGG-3', 5'-AGCAACACTTTTATCTAACACTGG-3', 5'-GCACTCTGTGTGGAGCAAAGAGG-3', 5'-GCAAATGAGTAAAGTTCTCCTGG-3', 5'-TGCAGTGATAGCACTCTGTGTGG-3', 5'-AACAGGATGAAAATGTATGGAGG-3', 5'-TTCATCCTGTTCTCTGTTCTGGG-3' or 5'-TTTCATCCTGTTCTCTGTTCTGG-3'.
  • a method for constructing CHO recombinant cells comprising the steps of:
  • the plasmids are respectively the expression vector for expressing protein in CHO cells, the sgRNA plasmid and the Cas9 plasmid corresponding to the target sequence;
  • the stable expression site obtained by the present invention is located within 100 bp upstream and downstream of base 103431 of CHO cell gene NW_003614889.1, that is, base 103331-103531, and can integrate foreign protein genes and perform stable expression.
  • the present invention integrates the target gene into the stable expression region through fixed-point integration, which solves the problem of unclear integration sites caused by random integration; the present invention uses base 103431 of the stable expression site NW_003614889.1 in the CHO genome
  • the site-specific integration of exogenous genes within the range of 103331-103531 bases upstream and downstream of the base overcomes the expression instability caused by the position effect and the repeated and tedious cell line screening process, reducing the original screening time of 6-12 months to 1-3 months, effectively shortening the R&D time for constructing stable expression cell lines and reducing costs.
  • Fig. 1 is a schematic diagram of fixed-point integration of the present invention
  • Figure 2 shows the expression of EGFP at different passages in cells constructed with different target sequences.
  • Figure 3 shows the expression of anti-EGFR at different passages in cells constructed with different target sequences.
  • the method for measuring the average fluorescence intensity of cells culture the cells until the confluence reaches about 90%, digest the cells with 0.25% trypsin, and terminate the digestion with a complete medium equal to the amount of trypsin, and collect the cells in a sterile centrifuge tube at 1000rpm/ Centrifuge for 5 min, discard the supernatant and resuspend with PBS, pass through a cell strainer and collect in a flow loading tube, and use a blank CHO-K1 cell as a control to analyze the fluorescence intensity of the cells with a flow cytometer.
  • the CHO-K1-2d9 cells expressing the Zsgreen1 reporter gene screened by high-throughput flow cytometry were cultured in an adherent culture until they were in good condition, and the CHO cells at this time were regarded as the 0th generation, and then cultured continuously for 20 days.
  • the expression of Zsgreen1 protein in cells at passages 0, 10, and 20 was observed under an inverted fluorescence microscope, and the average fluorescence intensity of cells at passages 0, 10, and 20 was detected by BD flow cytometry.
  • CHO-K1-2d9 cells could still express 100% Zsgreen1 protein in the adherent culture state, and Zsgreen1 protein between different passages
  • the expression levels are basically the same, and there is a strong green fluorescent signal.
  • the CHO-K1-2d9 cells that passed the verification of anchorage stability were subjected to suspension acclimation, and the CHO-K1-2d9 cells that were successfully acclimatized in suspension were continuously passaged for 60 passages, and the success of acclimation in suspension was regarded as the 0th passage.
  • the expression of Zsgreen1 protein in the cells at passages 0, 10, 20, 30, 40, 50, and 60 was observed under an inverted fluorescence microscope, and at the same time, the cells at passages 0, 10, 20, 30, 40, and 50 were detected by flow cytometry. Mean fluorescence intensity of cells at passage 60.
  • CHO-K1-2d9 cells could still express 100% Zsgreen1 protein in suspension culture state, and Zsgreen1 protein expression between different passages The levels are basically the same, and there is a strong green fluorescent signal. It shows that CHO-K1-2d9 cells can stably express the Zsgreen1 reporter gene, and at the same time, it shows that the integrated site of the lentivirus carrying the Zsgreen1 reporter gene is a stable expression site.
  • Collect CHO-K1-2d9 cells use the DNA extraction kit to extract the genome, use DraI, SspI, HpaI three restriction endonucleases to digest the genome at 37°C for 16-18h, and the digestion system is as follows:
  • the digested product was purified and recovered using a PCR purification kit, and the chromosome walking adapter GenomeWalker Adaptor was connected to both ends of the purified digested fragment.
  • the connection system was as follows:
  • a round of PCR reaction system is as follows:
  • the second round of PCR reaction system is as follows:
  • the second round of PCR products were subjected to agarose gel electrophoresis and gel recovery sequencing, and the sequencing was performed according to the kit Lenti-X Integration Site Analysis Kit (Clontech: 631263).
  • the lentivirus integration site information can be obtained by comparing the sequencing results with the CHO cell genome on NCBI.
  • the lentivirus integration site in CHO-K1-2d9 cells is located at base 103431 of the CHO cell genome NW_003614889.1.
  • Sequences in which the predicted editing efficiency was higher than 0.56 were selected as target sequences.
  • Target sequence 5'-ATCTTACTTTGCAACTACCAAGG-3'(SEQ ID NO.2), score 0.65
  • Target sequence 5'-CACTTTATCTAACACTGGCCAGG-3'(SEQ ID NO.3), score 0.62
  • Target sequence 5'-AGCAACACTTTTATCTAACACTGG-3'(SEQ ID NO.4), score 0.59
  • Target sequence 5'-GCACTCTGTGTGGAGCAAAGAGG-3'(SEQ ID NO.5), score 0.83
  • Target sequence 5'-GCAAATGAGTAAAGTTCTCCTGG-3'(SEQ ID NO.6), score 0.57
  • Target sequence 5'-TGCAGTGATAGCACTCTGTGTGG-3'(SEQ ID NO.7), score 0.68
  • Target sequence 5'-AACAGGATGAAAATGTATGGAGG-3'(SEQ ID NO.8), score 0.77
  • Target sequence 5'-TTCATCCTGTTCTCTGTTCTGGG-3'(SEQ ID NO.9), score 0.66
  • Target sequence 5'-TTTCATCCTGTTCTCTGTTCTGG-3'(SEQ ID NO.10), score 0.69
  • CRISPR/Cas9-mediated genome editing technology Using CRISPR/Cas9-mediated genome editing technology and homologous recombination, the green fluorescent protein gene (EGFP, 26.7KDa) will be integrated at the target site.
  • CRISPR/Cas9-mediated homologous recombination technology needs to construct sgRNA plasmid and Donor Plasmid, the construction process is as follows:
  • sgRNA-R1 5'TAAAACCCTTGGTAGTTGCAAAGTAAGAT 3'(SEQ ID NO.12)
  • sgRNA-R2 5'TAAAACCCTGGCCAGTGTTAGATAAAGTG 3'(SEQ ID NO.14)
  • sgRNA-R4 5'TAAAACCCCTCTTTGCTCCACACAGAGTGC 3'(SEQ ID NO.18)
  • sgRNA-R5 5'TAAAACCCAGGAGAACTTTACTCATTTGC 3'(SEQ ID NO.20)
  • sgRNA-R6 5'TAAAACCCACACAGAGTGCTATCACTGCA 3'(SEQ ID NO.22)
  • sgRNA-R8 5'TAAAACCCCAGAACAGAGAACAGGATGAA 3'(SEQ ID NO.26)
  • the PSK-u6-gRNA plasmid is digested with BBsI enzyme, and the vector after digestion is gel recovered;
  • Donor plasma The information of Donor plasma is shown in Figure 1, which was obtained by transforming the existing plasmid vector expressing EGFP. 5'arm and 3'arm are the upstream and downstream homology arms of the target sites recognized by each pair of sgRNAs, with a length of 600bp, and GOI is the integrated target gene.
  • the EGFP sequence of the target gene is carried by the original plasmid.
  • CRISPR/Cas9-mediated genome site-directed editing technology Using CRISPR/Cas9-mediated genome site-directed editing technology and homologous homology, the humanized antibody gene (anti-EGFR, 150KDa) expressing epidermal growth factor receptor was site-directedly integrated at the target site.
  • CRISPR/Cas9-mediated homologous recombination technology needs to construct sgRNA plasmid and Donor Plasmid, the construction process is as follows:
  • sgRNA-R1 5'TAAAACCCTTGGTAGTTGCAAAGTAAGAT 3'
  • sgRNA-R2 5'TAAAACCCTGGCCAGTGTTAGATAAAGTG 3'
  • sgRNA-R3 5'TAAAACCCAGTGTTAGATAAAGTGTTGCT 3'
  • sgRNA-R4 5'TAAAACCCCTCTTTGCTCCACACAGAGTGC 3'
  • sgRNA-R5 5'TAAAACCCAGGAGAACTTTACTCATTTGC 3'
  • sgRNA-R6 5'TAAAACCCACACAGAGTGCTATCACTGCA 3'
  • the PSK-u6-gRNA plasmid is digested with BBsI enzyme, and the vector after digestion is gel recovered;
  • Donor plasma information is shown in Figure 1. 5'arm and 3'arm are the upstream and downstream homology arms of the target site, respectively, with a length of 600bp, and GOI is the integrated target gene.
  • Detection method the cell lines obtained in Example 4 were continuously passaged for 60 passages, and the cells were collected for 15 passages per passage, and the cell fluorescence was detected with a flow cytometer and the intensity was detected, as shown in Figure 2.
  • the fluctuation range of green fluorescence intensity between the 0th passage and the 60th passage was not more than 30%.
  • Example 5 The cell line obtained in Example 5 was continuously passaged for 60 generations under serum-free culture conditions, and the cell fermentation supernatant of this generation was collected every 15 generations, and the anti-EGFR content in the fermentation broth was detected by ELISA kit , the analysis of the detection results showed that the cells constructed according to different target sequences in Example 5 had a stable ability to express anti-EGFR at different passages, as shown in FIG. 3 .
  • the 9 sets of target sequences screened in Example 3 of the present invention cover most of the upper, middle and downstream sequences within the 200 bp base of the present invention, and the 103331-103531 base range in the CHO cell gene NW_003614889.1 of the present invention is all A stable expression cell line with site-specific integration can be successfully constructed, and all of them can stably express the target protein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un site pour l'expression stable d'une protéine dans le gène de cellule CHO NW_003614889.1, et son utilisation, le site obtenu pour l'expression stable étant situé dans une plage de 100 pb en amont et en aval de la 103431e base du gène de cellule CHO NW_003614889.1, c'est-à-dire qu'un gène de protéine exogène peut être intégré aux 103331e-103531e bases et exprimé de manière stable. Dans la présente invention, un gène cible est intégré à la région susmentionnée pour une expression stable au moyen d'une intégration spécifique au site, ce qui résout le problème des sites d'intégration peu clairs causé par l'intégration aléatoire ; et au moyen de l'intégration spécifique au site d'un gène exogène au site pour une expression stable dans un génome CHO qui est situé dans une plage des 103331ème à 103531ème bases en amont et en aval de la 103431ème base du gène NW_003614889.1, les problèmes d'instabilité d'expression causés par l'effet de position et un processus de criblage de souches cellulaires répétitif et fastidieux sont surmontés.
PCT/CN2022/099466 2021-11-23 2022-06-17 Site pour l'expression stable de la protéine dans le gène de la cellule cho nw_003614889.1, et son utilisation Ceased WO2023093007A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111395511.4 2021-11-23
CN202111395511.4A CN113969284B (zh) 2021-11-23 2021-11-23 一种cho细胞基因nw_003614889.1内稳定表达蛋白质的位点及其应用

Publications (1)

Publication Number Publication Date
WO2023093007A1 true WO2023093007A1 (fr) 2023-06-01

Family

ID=79590155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/099466 Ceased WO2023093007A1 (fr) 2021-11-23 2022-06-17 Site pour l'expression stable de la protéine dans le gène de la cellule cho nw_003614889.1, et son utilisation

Country Status (2)

Country Link
CN (1) CN113969284B (fr)
WO (1) WO2023093007A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113969283B (zh) * 2021-11-23 2022-07-12 江南大学 一种cho细胞基因nw_003613756.1内稳定表达蛋白质的位点及其应用
CN113969284B (zh) * 2021-11-23 2022-07-12 江南大学 一种cho细胞基因nw_003614889.1内稳定表达蛋白质的位点及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081336A1 (fr) * 2006-01-13 2007-07-19 Five Prime Therapeutics, Inc. Vecteurs de mammiferes d'expression a haut niveau de proteines de recombinaison
CN102016025A (zh) * 2008-02-27 2011-04-13 国立大学法人北海道大学 用于用动物细胞大量生产源自外源基因的蛋白质的表达载体及其应用
CN109321604A (zh) * 2018-10-30 2019-02-12 江南大学 一种cho细胞基因组内nw_006882077-1稳定表达蛋白质的应用
WO2021214173A2 (fr) * 2020-04-22 2021-10-28 Lek Pharmaceuticals D.D. Super-amplificateurs pour l'expression de gènes recombinants dans des cellules cho
CN113969284A (zh) * 2021-11-23 2022-01-25 江南大学 一种cho细胞基因nw_003614889.1内稳定表达蛋白质的位点及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108441478A (zh) * 2017-02-16 2018-08-24 成都贝爱特生物科技有限公司 一种接受外源基因定点整合的基因工程细胞系
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
CN109295093B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006882456-1稳定表达蛋白质的应用
CN109207432B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006883358-1稳定表达蛋白质的应用
CN109136193B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006884764-1稳定表达蛋白质的应用
CN109295092B (zh) * 2018-10-30 2021-06-29 江南大学 一种cho细胞基因组内nw_003613638-1稳定表达蛋白质的应用
CN109337927B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006880285-1稳定表达蛋白质的应用
CN110982790B (zh) * 2019-12-26 2022-07-19 海珂分子（北京）科技有限责任公司 一种用于蛋白展示和表达的细胞株及其制备方法和应用
CN113969283B (zh) * 2021-11-23 2022-07-12 江南大学 一种cho细胞基因nw_003613756.1内稳定表达蛋白质的位点及其应用
CN114085841B (zh) * 2021-11-23 2022-07-15 江南大学 一种cho细胞基因nw_003614092.1内稳定表达蛋白质的位点及其应用
CN114058625B (zh) * 2021-11-25 2022-07-15 江南大学 一种cho细胞基因nw_003613781.1内稳定表达蛋白质的位点及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081336A1 (fr) * 2006-01-13 2007-07-19 Five Prime Therapeutics, Inc. Vecteurs de mammiferes d'expression a haut niveau de proteines de recombinaison
CN102016025A (zh) * 2008-02-27 2011-04-13 国立大学法人北海道大学 用于用动物细胞大量生产源自外源基因的蛋白质的表达载体及其应用
CN109321604A (zh) * 2018-10-30 2019-02-12 江南大学 一种cho细胞基因组内nw_006882077-1稳定表达蛋白质的应用
WO2021214173A2 (fr) * 2020-04-22 2021-10-28 Lek Pharmaceuticals D.D. Super-amplificateurs pour l'expression de gènes recombinants dans des cellules cho
CN113969284A (zh) * 2021-11-23 2022-01-25 江南大学 一种cho细胞基因nw_003614889.1内稳定表达蛋白质的位点及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HU WANWAN, DING XUEFENG;CAI YANFEI;CHEN YUN;DUAN ZUOYING;JIN JIAN;LI HUAZHONG: "Site-specific integration and stable expression of exogenous protein at a novel site on CHO cell chromosome", JOURNAL OF CHINA PHARMACEUTICAL UNIVERSITY, NAJING, CN, vol. 52, no. 4, 12 April 2021 (2021-04-12), CN , pages 487 - 495, XP093068728, ISSN: 1000-5048, DOI: 10.11665/j.issn.1000-5048.20210412 *

Also Published As

Publication number Publication date
CN113969284A (zh) 2022-01-25
CN113969284B (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
CN114058625B (zh) 一种cho细胞基因nw_003613781.1内稳定表达蛋白质的位点及其应用
WO2023093006A1 (fr) Site capable d'exprimer de manière stable une protéine dans le gène de cellule cho nw_003614092,1 et son utilisation
CN106755091A (zh) 基因敲除载体，mh7a细胞nlrp1基因敲除方法
CN107893073B (zh) 一种筛选谷氨酰胺合成酶缺陷型hek293细胞株的方法
CN104379753A (zh) 位点特异性整合
CN109880851B (zh) 用于富集CRISPR/Cas9介导的同源重组修复细胞的筛选报告载体及筛选方法
CN109136193B (zh) 一种cho细胞基因组内nw_006884764-1稳定表达蛋白质的应用
WO2023093007A1 (fr) Site pour l'expression stable de la protéine dans le gène de la cellule cho nw_003614889.1, et son utilisation
WO2023093005A1 (fr) Site capable d'exprimer de manière stable une protéine dans le gène de cellule cho nw_003613756,1 et son utilisation
US11732276B2 (en) Use of genomic NW_006882077.1 in CHO cell for stably expressing a protein
WO2020088300A1 (fr) Utilisation de nw_003613638-1 dans un génome de cellule cho pour une expression protéique stable
US11692204B2 (en) Use of genomic NW_006880285.1 in CHO cell for stably expressing a protein
WO2020088299A1 (fr) Application de nw_006883358,1 dans un génome de cellule cho pour une expression stable de protéine
WO2020088302A1 (fr) Utilisation de nw_006882456-1 dans le génome de cellule cho dans l'expression stable de protéine
CN113355360A (zh) 一种gs基因敲除cho-k1细胞株的构建方法及悬浮细胞单克隆化
EA037273B1 (ru) Экспрессионная кассета
CN114540352A (zh) 一种多核苷酸、载体元件及表达载体和宿主细胞及应用
US11136598B2 (en) Method for cell line development
WO2023246626A1 (fr) Cellule à intégration ciblée, son procédé de préparation et procédé de production d'un produit d'expression de gène cible
CN110982790B (zh) 一种用于蛋白展示和表达的细胞株及其制备方法和应用
CN120249293A (zh) 一种hek293t细胞基因ng_027973.1内稳定表达蛋白质的位点及其应用
WO2023050158A1 (fr) Procédé pour réaliser une édition sur plusieurs bases
CN121022941A (zh) 一种基于cho细胞基因组内nc_048604-1位点高效表达外源蛋白的方法
CN120005831A (zh) Cho整合位点及其应用
CN120775918A (zh) Tp63基因在提高外源重组蛋白表达量中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22897104

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22897104

Country of ref document: EP

Kind code of ref document: A1